<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03972735</url>
  </required_header>
  <id_info>
    <org_study_id>2018-A03237-48</org_study_id>
    <nct_id>NCT03972735</nct_id>
  </id_info>
  <brief_title>Assessment of the Effectiveness of the NECT Program</brief_title>
  <acronym>NECT</acronym>
  <official_title>Randomized Controlled Study on the Efficacy of the NECT Program (Cognitive Therapy and Narrative Development) on Improving Social Functioning in People With Severe Psychic Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Center Alpes-Isère</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hôpital le Vinatier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinique du Dauphiné</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CH Annecy Genevois</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Esquirol</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHS LE VALMONT</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Center Alpes-Isère</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Self-stigma refers to the transformation process wherein a person's previously held social
      identity is progressively replaced by a devalued and stigmatized view of oneself termed
      &quot;illness identity&quot;. Self-Stigma is a severe problem in Serious Mental Illness (SMI).
      Self-stigma prevalence is high (41.7% of the 1229 participants with SZ and 21.7% of the 1182
      participants with mood disorders had moderate to high levels of IS in the GAMIAN-Europe
      study). Self-stigma was negatively associated with self-esteem, social function, wellbeing,
      quality of life or personal recovery and positively associated with psychiatric symptoms and
      depression. Several psychosocial interventions (mostly combinations of psychoeducation and
      cognitive behaviour therapy) have been designed to reduce self-stigma and its impact on
      clinical and functional outcomes, with preliminary effects on self-stigma, insight and
      self-efficacy.

      Narrative Enhancement and Cognitive Therapy (NECT) is a manualized structured 20-session
      group-based intervention . Conducted by two trained facilitators the sessions combine
      psychoeducation, cognitive restructuring and story-telling exercises to reduce self-stigma.
      Developed in USA, NECT was adapted in Israel and Sweden. NECT showed effectiveness in
      reducing self-stigma and in improving self-esteem and quality of life. Despite being
      effective on changing coping strategies, NECT effectiveness on social function is still
      unclear.

      The present study aims to validate NECT French adaptation and to evaluate its effectiveness
      on social function, self-stigma, psychiatric symptoms, self-esteem, wellbeing, quality of
      life and personal recovery in SMI participants (schizophrenia, bipolar disorder, borderline
      personality disorder)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>stepped-wedge</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Personal and Social Performance Scale</measure>
    <time_frame>Changes between baseline function, at 6, 12 and 18 months of follow-up</time_frame>
    <description>Changes in the aggregates (average) of standardized performance levels : z-scores of social function (0 to 100) after NECT Program</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Internalized Stigma of Mental Illness (ISMI) scale</measure>
    <time_frame>Changes between baseline function, at 6, 12 and 18 months of follow-up</time_frame>
    <description>self-assessment of internalized stigma (mean score of total self-stigma ranging from 1 to 4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive and Negative Symptoms Scale for Schizophrenia (PANSS)</measure>
    <time_frame>Changes between baseline function, at 6, 12 and 18 months of follow-up</time_frame>
    <description>Changes in the aggregates (average) of standardized performance levels : z-scores of positive and negative symptoms (minimum score 30- maximum score 210) of schizophrenia after NECT Program</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MADRS (Montgomery-Asberg Depression Rating)</measure>
    <time_frame>Changes between baseline function, at 6, 12 and 18 months of follow-up</time_frame>
    <description>Changes in the aggregates (average) of standardized performance levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BIRCHWOOD INSIGHT SCALE</measure>
    <time_frame>Changes between baseline function, at 6, 12 and 18 months of follow-up</time_frame>
    <description>Changes in the aggregates (average) of standardized performance levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MARS (Medication Adherence Rating Scale)</measure>
    <time_frame>Changes between baseline function, at 6, 12 and 18 months of follow-up</time_frame>
    <description>self-assesment of adherence into treatment (minimum 1-maximum 10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WEMWBS (Warwick Edinburgh Mental Well Being Scale) )</measure>
    <time_frame>Changes between baseline function, at 6, 12 and 18 months of follow-up</time_frame>
    <description>self assessment of mental well being</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SERS (Self-Esteem Rating Scale)</measure>
    <time_frame>Changes between baseline function, at 6, 12 and 18 months of follow-up</time_frame>
    <description>Changes in the aggregates (average) of standardized performance levels : z-scores (minimum score 10-maximum score 70) in self-assessment of self-esteem</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>S-QOL (Subjective Quality of Life)</measure>
    <time_frame>Changes between baseline function, at 6, 12 and 18 months of follow-up</time_frame>
    <description>sel-assessment of quality of life (minimum 0, maximum 100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STORI Stages of Recovery Instrument</measure>
    <time_frame>Changes between baseline function, at 6, 12 and 18 months of follow-up</time_frame>
    <description>Self-assessment of personal recovery (maximum stage of recovery ranging from 0 to 5</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Bipolar Disorder</condition>
  <condition>Borderline Personality Disorder</condition>
  <condition>Social Function</condition>
  <condition>Self-stigma</condition>
  <arm_group>
    <arm_group_label>NECT + follow up</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Narrative Development and Cognitive Therapy (NECT) is a 12 session group-based manualized intervention combining psychoeducation, cognitive restructuring and narrative enhancement. The 2 hours sessions are conducted by two trained facilitators.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAU</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug treatment (antipsychotic, mood stabilizing) for people with schizophrenia or with bipolar disorder
Support in day-care hospital
No intervention specifically targeting self-stigma reduction or improvements in social functioning (social cognitive remediation or social skills training)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Psychiatric interview</intervention_name>
    <description>PANSS, MADRS, PSP, YMRS</description>
    <arm_group_label>NECT + follow up</arm_group_label>
    <arm_group_label>TAU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Clinical, diagnostic and functional evaluation</intervention_name>
    <description>ISMI, STORI, SERS, S-QOL, WEWMBS, BIRCHWOOD, MARS</description>
    <arm_group_label>NECT + follow up</arm_group_label>
    <arm_group_label>TAU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>neuropsychological assessment</intervention_name>
    <description>WAIS IV, BEM 144, TMT A, TMT B, D2-R, V-LIS</description>
    <arm_group_label>NECT + follow up</arm_group_label>
    <arm_group_label>TAU</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NECT PROGRAM</intervention_name>
    <description>Narrative Development and Cognitive Therapy (NECT) is a 12 session group-based manualized intervention combining psychoeducation, cognitive restructuring and narrative enhancement. The 2h sessions are conducted by two trained facilitators.</description>
    <arm_group_label>NECT + follow up</arm_group_label>
    <arm_group_label>TAU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of schizophrenia, schizoaffective disorder, schizotypal disorder,
             schizophreniform disorder, bipolar I or II disorder, borderline personality disorder
             (DSM-V criteria, APA, 2013).

          -  Clinical stability since 3 months (total PANSS score &lt;120, MADRS score &lt;15 and YMRS
             &lt;12 for patients with schizophrenia and MADRS score &lt;15 and YMRS &lt;12 for patients with
             bipolar disorder).

          -  Patients who gave informed consent to participate in the study.

          -  Affiliated to a social security scheme or beneficiary of such a scheme.

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  Criteria relating to the associated pathologies entailing particular risks:

          -  Neurological disorders of vascular, infectious or neurodegenerative origin.

          -  Taking somatic drugs with a cerebral or mental impact (eg corticosteroids).

          -  Presence of an associated intellectual disability.

          -  Prohibited treatments and procedures:

          -  Subject in exclusion period of another study.

          -  Simultaneous participation in other programs having an impact on social functioning or
             self-stigmatization: remediation of social cognition, individual and group care
             targeting self-stigmatization and training in social skills.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien JD DUBREUCQ, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Center Alpes-Isère</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julien JD DUBREUCQ, MD</last_name>
    <phone>+33 4 76 58 88 00</phone>
    <email>jdubreucq@ch-alpes-isere.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas TC COHEN, CRA</last_name>
    <phone>+33 4 76 58 88 13</phone>
    <email>tcohen@ch-alpes-isere.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ch Annecy-Genevois</name>
      <address>
        <city>Annecy</city>
        <state>Aura</state>
        <zip>74000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Céline CR ROUSSEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Céline CR ROUSSEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ch Le Vinatier</name>
      <address>
        <city>Bron</city>
        <state>Aura</state>
        <zip>69678</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas NF FRANCK, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas NF FRANCK, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de CLERMONT-FERRAND</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Aura</state>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ISABELLE IC CHEREAU, MD</last_name>
    </contact>
    <investigator>
      <last_name>ISABELLE IC CHEREAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital, Grenoble</name>
      <address>
        <city>Grenoble</city>
        <state>Aura</state>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mircea MP POLOSAN, MD</last_name>
      <email>mpolosan@chu-grenoble.Fr</email>
    </contact>
    <investigator>
      <last_name>Mircea MP POLOSAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHS Esquirol</name>
      <address>
        <city>Limoges</city>
        <state>Aura</state>
        <zip>87000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie EL LEGROS LAFARGE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Emilie EL LEGROS LAFARGE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique du Dauphiné</name>
      <address>
        <city>Seyssins</city>
        <state>Aura</state>
        <zip>38180</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth EG GIRAUD BARO, MD</last_name>
      <email>egiraudbaro@orange.fr</email>
    </contact>
    <investigator>
      <last_name>Elisabeth EG GIRAUD BARO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chs Le Valmont</name>
      <address>
        <city>Valence</city>
        <state>Aura</state>
        <zip>26000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Motassem MB BAKRI, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Motassem MB BAKRI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mickael MB BACCONNIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier DV VAQUETTE, DV</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>E.P.S.M. Ariane</name>
      <address>
        <city>Caen</city>
        <state>Normandie</state>
        <zip>14012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elodie ED DECERLE, MD</last_name>
    </contact>
    <investigator>
      <last_name>ELodie ED DECERLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital La Colombière, University Hospital Montpellier</name>
      <address>
        <city>Montpellier</city>
        <state>Occitanie</state>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Rainteau, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas Rainteau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Center SAINTE MARIE</name>
      <address>
        <city>Nice</city>
        <state>Paca</state>
        <zip>06009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yves JG GIORDANA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Yves JG GIORDANA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service des Specialités psychiatriques</name>
      <address>
        <city>Geneva</city>
        <zip>1201</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène HR RICHARD LEPOURRIEL, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hélèné HR RICHARD LEPOURRIEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Bellack AS, Brown SA. Psychosocial treatments for schizophrenia. Curr Psychiatry Rep. 2001 Oct;3(5):407-12. Review.</citation>
    <PMID>11559478</PMID>
  </reference>
  <reference>
    <citation>Brohan E, Elgie R, Sartorius N, Thornicroft G; GAMIAN-Europe Study Group. Self-stigma, empowerment and perceived discrimination among people with schizophrenia in 14 European countries: the GAMIAN-Europe study. Schizophr Res. 2010 Sep;122(1-3):232-8. doi: 10.1016/j.schres.2010.02.1065. Epub 2010 Mar 26.</citation>
    <PMID>20347271</PMID>
  </reference>
  <reference>
    <citation>Corrigan PW, Larson JE, Rüsch N. Self-stigma and the &quot;why try&quot; effect: impact on life goals and evidence-based practices. World Psychiatry. 2009 Jun;8(2):75-81.</citation>
    <PMID>19516923</PMID>
  </reference>
  <reference>
    <citation>Corrigan PW, Kosyluk KA, Rüsch N. Reducing self-stigma by coming out proud. Am J Public Health. 2013 May;103(5):794-800. doi: 10.2105/AJPH.2012.301037. Epub 2013 Mar 14. Review.</citation>
    <PMID>23488488</PMID>
  </reference>
  <reference>
    <citation>Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW, Lehman A, Tenhula WN, Calmes C, Pasillas RM, Peer J, Kreyenbuhl J; Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull. 2010 Jan;36(1):48-70. doi: 10.1093/schbul/sbp115. Epub 2009 Dec 2. Review.</citation>
    <PMID>19955389</PMID>
  </reference>
  <reference>
    <citation>Fung KM, Tsang HW, Cheung WM. Randomized controlled trial of the self-stigma reduction program among individuals with schizophrenia. Psychiatry Res. 2011 Sep 30;189(2):208-14. doi: 10.1016/j.psychres.2011.02.013. Epub 2011 Mar 5.</citation>
    <PMID>21377738</PMID>
  </reference>
  <reference>
    <citation>Lysaker PH, Bond G, Davis LW, Bryson GJ, Bell MD. Enhanced cognitive-behavioral therapy for vocational rehabilitation in schizophrenia: Effects on hope and work. J Rehabil Res Dev. 2005 Sep-Oct;42(5):673-82.</citation>
    <PMID>16586193</PMID>
  </reference>
  <reference>
    <citation>Lysaker PH, Roe D, Yanos PT. Toward understanding the insight paradox: internalized stigma moderates the association between insight and social functioning, hope, and self-esteem among people with schizophrenia spectrum disorders. Schizophr Bull. 2007 Jan;33(1):192-9. Epub 2006 Aug 7.</citation>
    <PMID>16894025</PMID>
  </reference>
  <reference>
    <citation>Rüsch N, Lieb K, Bohus M, Corrigan PW. Self-stigma, empowerment, and perceived legitimacy of discrimination among women with mental illness. Psychiatr Serv. 2006 Mar;57(3):399-402.</citation>
    <PMID>16525000</PMID>
  </reference>
  <reference>
    <citation>Vauth R, Kleim B, Wirtz M, Corrigan PW. Self-efficacy and empowerment as outcomes of self-stigmatizing and coping in schizophrenia. Psychiatry Res. 2007 Feb 28;150(1):71-80. Epub 2007 Jan 30.</citation>
    <PMID>17270279</PMID>
  </reference>
  <reference>
    <citation>Yanos PT, Roe D, Markus K, Lysaker PH. Pathways between internalized stigma and outcomes related to recovery in schizophrenia spectrum disorders. Psychiatr Serv. 2008 Dec;59(12):1437-42. doi: 10.1176/appi.ps.59.12.1437.</citation>
    <PMID>19033171</PMID>
  </reference>
  <results_reference>
    <citation>Livingston JD, Boyd JE. Correlates and consequences of internalized stigma for people living with mental illness: a systematic review and meta-analysis. Soc Sci Med. 2010 Dec;71(12):2150-61. doi: 10.1016/j.socscimed.2010.09.030. Epub 2010 Oct 12. Review.</citation>
    <PMID>21051128</PMID>
  </results_reference>
  <results_reference>
    <citation>Lucksted A, Drapalski AL, Brown CH, Wilson C, Charlotte M, Mullane A, Fang LJ. Outcomes of a Psychoeducational Intervention to Reduce Internalized Stigma Among Psychosocial Rehabilitation Clients. Psychiatr Serv. 2017 Apr 1;68(4):360-367. doi: 10.1176/appi.ps.201600037. Epub 2016 Dec 1.</citation>
    <PMID>27903136</PMID>
  </results_reference>
  <results_reference>
    <citation>Roe D, Hasson-Ohayon I, Mashiach-Eizenberg M, Derhy O, Lysaker PH, Yanos PT. Narrative enhancement and cognitive therapy (NECT) effectiveness: a quasi-experimental study. J Clin Psychol. 2014 Apr;70(4):303-12. doi: 10.1002/jclp.22050. Epub 2013 Oct 2.</citation>
    <PMID>24114797</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>May 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Center Alpes-Isère</investigator_affiliation>
    <investigator_full_name>Dr Julien Dubreucq</investigator_full_name>
    <investigator_title>Medical doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Personality Disorders</mesh_term>
    <mesh_term>Borderline Personality Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

